Ozempic Vision Loss and Blindness Lawsuit (NAION): A Separate MDL
Questions about this case?
AI Legal Assistant · free · answers in seconds · general information, not legal advice
Sudden, usually permanent vision loss in one eye — the injury behind what is often called the “Ozempic blindness” lawsuit — differs from the stomach-paralysis cases and has its own court docket. 216 cases pending as of September 1, 2026, up from 110 on June 1. No settlement exists, and the court will test the science first, on a schedule that runs into 2027.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuits Allege
Plaintiffs allege that semaglutide — sold as Ozempic, Wegovy and Rybelsus — can cause NAION (non-arteritic anterior ischemic optic neuropathy), and that the manufacturers failed to warn patients and physicians about that risk. NAION is sudden vision loss caused by insufficient blood flow to the optic nerve. It usually affects one eye, and the damage is generally permanent — there is no established treatment that restores the lost vision. The court’s list of drugs in the MDL also includes Novo Nordisk’s Saxenda and Eli Lilly’s Trulicity, Mounjaro and Zepbound, though the published research has focused on semaglutide. Novo Nordisk describes NAION as a very rare eye condition and disputes that it is a drug side effect in the legal sense.
Case Details
MDL No. 3163, In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, U.S. District Court for the Eastern District of Pennsylvania, before Judge Karen S. Marston. Created by JPML transfer order on December 15, 2025. The JPML report dated September 1, 2026 lists 216 pending actions — up from 110 on June 1 and 200 on August 3. This is a separate case from MDL 3094, the much larger GLP-1 litigation over gastrointestinal injuries (4,022 pending on the same date), which sits before the same judge in the same court. The JPML declined to fold the vision cases into MDL 3094: the injury is different, and a separate docket lets the judge decide how closely to coordinate the two.
Current Status — Verified September 27, 2026
Follow this case
There's no claim deadline yet. We'll email you if a settlement opens a claim period.
Who May Have a Case
The profile is a patient who took a GLP-1 drug for diabetes or weight loss — semaglutide (Ozempic, Wegovy or Rybelsus) or another drug on the court’s list (Saxenda, Trulicity, Mounjaro, Zepbound) — and then experienced sudden vision loss in one eye diagnosed as NAION by an ophthalmologist or neuro-ophthalmologist. Two things decide these cases: the diagnosis itself, which requires an eye specialist's examination and is documented in ophthalmology records, and the timeline — when the medication started relative to when vision was lost. Because NAION also occurs in people who never took these drugs, and shares risk factors with diabetes itself, causation in an individual case is genuinely contested. Before any individual case is weighed, though, the court will decide the general question — whether these drugs can cause NAION at all — on a schedule that runs into the second half of 2027.
Settlement Amounts: What This Could Pay (Honest Answer)
Case Timeline
- 1
July 2024: The Harvard-affiliated study
Researchers at Mass Eye and Ear publish in JAMA Ophthalmology a retrospective cohort finding a substantially higher NAION rate among semaglutide patients. The authors themselves flag limitations: small case numbers, a single specialist centre, and a study population that was largely white.
- 2
January 2025: European regulators open a review
The EMA's safety committee begins reviewing semaglutide, noting that two observational studies suggested increased risk while two others did not — the signal was mixed from the start.
- 3
June 2025: NAION classified as a very rare side effect
The EMA's PRAC concludes NAION is a very rare side effect of semaglutide medicines — up to 1 in 10,000 treated patients — and recommends product information be updated: seek immediate medical advice on sudden vision loss, and stop treatment if NAION is confirmed.
- 4
December 15, 2025: The NAION cases get their own MDL
The JPML creates MDL 3163 in the Eastern District of Pennsylvania, separating vision-loss claims from the far larger gastrointestinal GLP-1 litigation.
- 5
July 2, 2026: Causation and warnings go first
Case Management Order No. 12 grants the manufacturers’ request to litigate two cross-cutting issues first: whether GLP-1 drugs can cause NAION (general causation) and whether federal law preempts the failure-to-warn claims or the existing warnings were adequate. The court rejected the plaintiffs’ “pilot cases” alternative; bellwether selection would come only after those issues are decided.
- 6
August 27, 2026: The schedule through 2027
Case Management Order No. 14 sets the deadlines: plaintiffs’ Master Complaint by October 28, 2026; fact discovery by December 18, 2026 for Lilly and February 26, 2027 for Novo Nordisk; plaintiffs’ expert reports by March 26, 2027 and the defense’s by April 23, 2027; expert depositions by June 4, 2027; Rule 702 and summary-judgment motions by July 2, 2027, with briefing closing August 31, 2027. The order sets no trial date.
- 7
September 1, 2026: 216 cases pending
The JPML’s monthly report lists 216 pending actions — up from 29 in early January, 110 on June 1 and 200 on August 3. The August increase of 16 cases followed gains of 36 and 54 in the two months before. The JPML’s historical total is also 216, so none of the cases has been closed.
What to Be Careful About
GLP-1 drugs are the most marketed medications in America right now, and the legal advertising around them is equally aggressive.
“Ozempic settlement — claim your payout”
There is no settlement in either GLP-1 MDL, and no claim form. Any site inviting you to claim a payout today is generating leads, not distributing money.
Blurring the two GLP-1 cases
The stomach-paralysis cases (MDL 3094, 4,022 pending) and the vision-loss cases (MDL 3163, 216 pending) — both as of September 1, 2026 — are separate dockets over separate injuries, on separate schedules. Sites that merge them into one big number, or attach one docket’s court dates to the other, are inflating or confusing the picture.
“Stop taking your medication to preserve your claim”
Nobody outside your medical team should be advising you about your prescription. Stopping diabetes or weight-management medication has its own serious risks — that decision belongs with your doctor, not with a legal marketer.
Ozempic Vision Loss and Blindness (NAION) FAQs
Is there an Ozempic blindness lawsuit settlement? What are the settlement amounts?
No. MDL 3163 has no settlement, no verdict and no trial date, so there are no settlement amounts — no case in this litigation has paid anything, and there is no administrator or claim form. No court has set or approved any amount, and the dollar figures circulating online are estimates by law firms and legal-marketing sites — none of them comes from a court record, a verdict or an offer in this litigation. Under the court's August 27, 2026 schedule, the first test of the science (Rule 702 and summary-judgment motions) is fully briefed on August 31, 2027, and under the court's plan bellwether cases would be picked only after the ruling on those motions.
What exactly is NAION?
Non-arteritic anterior ischemic optic neuropathy: sudden loss of vision caused by insufficient blood flow to the optic nerve, usually in one eye. It typically happens without pain and is generally permanent — there is no established treatment that restores the lost vision.
European regulators called it 'very rare' — does that help or hurt these cases?
Both, in different ways. The EMA's June 2025 conclusion that NAION is a very rare side effect — up to 1 in 10,000 treated patients — is an acknowledgment that the association is real enough to warn about, which plaintiffs point to. But 'very rare' also frames the risk as small, which the defense points to. Regulatory language is not a causation finding in an individual case.
I have diabetes, which also affects eyes. Does that end my case?
No, but it is the central battleground. Diabetes and its vascular effects are independent risk factors for NAION, so the defense will argue the underlying condition explains it. That is exactly why ophthalmology records and the timing of symptom onset relative to starting the medication matter so much.
Is this the same as the Ozempic stomach lawsuits?
No. Those are MDL 3094 — gastroparesis, ileus and related gastrointestinal injuries, with 4,022 cases pending as of September 1, 2026. Vision loss has its own MDL 3163 with 216 cases. Same judge and same court, but different dockets, different injuries, different medical evidence and different schedules: the Rule 702 hearing held September 14–18, 2026 was in MDL 3094.
What about Mounjaro or Zepbound?
Tirzepatide products are named in the litigation, but the published NAION research and the European regulatory action focused on semaglutide. Whether the evidence extends equally to tirzepatide is not settled — an attorney would assess that against your specific medication history.
What records should I gather?
The ophthalmology or neuro-ophthalmology records containing the NAION diagnosis, imaging and visual-field testing, your full prescription history with start dates, and documentation of how the vision loss affects work and daily life. The diagnosis and the dates are the case.
Is this the 'Ozempic blindness lawsuit'? Does NAION make you blind?
These are the cases usually meant by that phrase, but 'blindness' overstates what most patients experience. NAION typically strikes one eye, suddenly and without pain, and the damage varies widely: in one natural-history review cited by EyeWiki, the American Academy of Ophthalmology's reference, about half of patients had 20/30 vision or better in the affected eye and nearly a quarter had 20/200 or worse; total loss of light perception is exceptionally rare, although most patients lose part of their field of vision, most often the lower half. The second eye is affected in roughly 15% to 24% of patients within five years. Under Social Security rules, legal blindness means 20/200 or less in the better eye with glasses (or a visual field of 20 degrees or less), so NAION in one eye usually does not make someone legally blind. Some patients regain part of the lost vision in the first months, but no treatment has been proven to restore it, and the lawsuits claim permanent vision loss.
Ozempic blindness lawsuit: how many cases are there?
216 cases were pending in MDL 3163 on September 1, 2026, according to the Judicial Panel on Multidistrict Litigation — up from 29 in early January 2026 and 110 on June 1. None has been resolved yet. Most target Novo Nordisk: of the 137 cases counted on June 15, 2026, only 19 named Eli Lilly (maker of Trulicity, Mounjaro and Zepbound), according to the court. Related cases filed in state courts are not in this count; in July 2026 the court described them as still at the pleadings stage. The separate gastrointestinal MDL 3094 had 4,022 cases on the same date.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.